Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
Martin RudwaleitAtul DeodharLars BauerLianne GenslerBengt HoepkenThomas KumkeSimone Emanuele AuteriMindy KimWalter P MaksymowychPublished in: RMD open (2024)
In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI-/CRP+ and MRI+/CRP- subgroups.